Antineutrophil cytoplasmic antibody positivity and clinical implications in COVID-19.
Serdar Can GüvenHakan ApaydınBahar Özdemir UlusoyBerkan Armağanİhsan AteşAbdulsamet ErdenOrhan KüçükşahinAhmet OmmaPublished in: Future virology (2022)
Aim: To investigate clinical implications of antineutrophil cytoplasmic antibody (ANCA) positivity detected in COVID-19 patients during follow up. Materials and methods: A retrospective survey in a hospital database was carried out to detect COVID-19 patients in which ANCAs had been tested. Clinical, laboratory and imaging data were collected from this hospital database and compared between ANCA-negative and -positive patients. Results: ANCAs were tested in 87 COVID-19 patients. Eight had positivity in at least one ANCA test. COVID-19 symptoms on admission and rate of pulmonary involvement were similar. Acute phase reactant levels were higher in ANCA-positive patients. Rate of mortality was higher in the ANCA-positive group without statistical significance. Conclusion: ANCA positivity detected during COVID-19 in patients without a prior diagnosis of any rheumatic condition may be related with worse outcomes.
Keyphrases
- end stage renal disease
- sars cov
- ejection fraction
- newly diagnosed
- coronavirus disease
- chronic kidney disease
- healthcare
- emergency department
- peritoneal dialysis
- rheumatoid arthritis
- type diabetes
- cardiovascular disease
- depressive symptoms
- high resolution
- adverse drug
- artificial intelligence
- patient reported outcomes
- electronic health record